FDA has issued draft guidance describing the agency’s current thinking on several topics relevant to clinical research related to the development of drugs containing cannabis or cannabis-derived compounds.
Similar Posts
Insufflation Unit Recall: Olympus Removes High Flow Insufflation Units
Olympus is removing certain High Flow Insufflation Unit models due to software issues that may lead to overpressure events.Ultra Seal Corporation – 624650 – 09/25/2024
CGMP/Finished Pharmaceuticals/AdulteratedKenz Henz Recalls “Pastured Raised Eggs” Because of Possible Health Risk
Kenz Henz of Santa Fe, TX, is recalling its 12 count packages of “Grade AA Large Pasture Raised eggs” because they have the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weaFDA Advances Drug Development Innovation by Establishing ISTAND as Permanent Qualification Program
ISTAND supports innovative, science-driven approaches that improve drug development and regulatory decision-making, ultimately helping to make therapies available to address patients’ unmet needs.Weight Loss, Male Enhancement and Other Products Sold Online or in Stores May Be Dangerous
Consumers cannot be confident that certain products, including weight loss and male enhancement products, sold on online marketplaces like Amazon and eBay or in stores, are safe to use.Xtreme Tools International, Inc. – 706053 – 06/25/2025
CGMP/Finished Pharmaceuticals/Adulterated